Læknablaðið - 15.08.1984, Blaðsíða 37

LÆKNABLAÐIÐ
199
61 % were ER + . Of the 25 samples in which both
receptors were measured, 40 % were ER+PR+,
24 % were ER+PR-, 36 % were ER“PR- and 0 %
were ER_PR + . Thus relatively fewer samples from
metastatic cancer contain receptors, which indicates
that receptor-negative cells more easily form meta-
static growth.
The receptor status in the primary breast cancer
samples was correlated with the menopausal stage
of the patient. The premenopausal patients showed
higher proportion of positive results while having
lower receptor content than the postmenopausal
group. This might indicate some difference in onco-
genesis between premenopausal and postmenopausal
breast cancer.
Receptor status in samples taken as biopsy
specimens (103) was compared to those taken as
mastectomy specimens (51 samples). The results
show reduced number of positive (ER+ and PR + )
samples in the mastectomy samples compared with
the biopsy samples, especially in the low positive
group (<50 fmol/mg). The number of samples
containing only one type of receptor (ER + PR- or
ER-PR + ) was higher in the mastectomy samples
than the biopsy samples. This indicates that there is
more autolytic loss of receptors in the mastectomy
specimens due to insatisfactory cooling and break-
down of receptors during the mastectomy operati-
on. A tumor with a low level of ER and/or PR might
yield a false negative result in a mastectomy
specimen.
HEIMILDIR
1) Seibert K., Lippman M. Hormone receptors in
breast cancer. Clin Onc 1982; 1 (3); 735-94.
2) i iahnel R, Woodings T, Vivian AB. Prognostic
value of estrogen receptors in primary breast
cancer. Cancer 1979;44:671-5.
3) Maynard PV, Blamey RW, Elston CW, Haybitt-
le JL, Griffiths K. Estrogen receptor assay in
primary breast cancer and early recurrence of
the disease. Cancer Res 1978; 38: 4292-5.
4) Knight WA, Livingstone RB, Gregory EJ,
McGuire WL. Estrogen receptor as an inde-
pendent prognostic factor for early recurrence
in breast cancer. Cancer Res 1977; 37: 4669-71.
5) Elwood JM, Goodolphine W. Oestrogen recep-
tors in breast tumours: associations with age,
menopausal status and epidemiological and
clinical features in 735 patients. Br J Cancer
1980;42:635-44.
6) Stewart JF, King RJ, Sexton SA et al. Oestrogen
receptors, sites of metastatic disease and survi-
val in recurrent breast cancer. Eur J Cancer 1980;
17 (4); 449-53.
7) Osborne CK, McGuire WL. Current use of
steroid hormone receptor assays in the treat-
ment of breast cancer. In: The Surgical Clinics
of North America 1978; 58 (4); 777-88.
8) Keenan EJ, Hart NE. Specimen handling guide-
lines for steroid receptor analysis in breast
cancer. Lab Med 1981; 12 (5); 275-8.
9) Koenders A, Thorpe SM. Standardization of
steroid receptor assays in human breast cancer-
I. Reproducibility of estradiol and progesterone
receptor assays. Eur J Cancer Clin Oncol 1983;
19(9); 1221-9.
10) McGuire WL, DeLaGarza M. Improved sensiti-
vity in the measurement of estrogen receptor in
human breast cancer. J Clin Endocrinol Metab
1973;37:986-9.
11) Bradford NM. A rapid and sensitive method for
the quantitation of microgram quantities of
protein utilizing the principle of protein dye-
binding. Anal Biochem 1976; 72: 248-54.
12) Scatchard G. The attraction of proteins for
small molecules and ions. Ann NY Acad Sci
1949;51:660-72.
13) Benraad T, Koenders A. Estradiol receptor
activity in lyophilized calf uterus and human
breast tumor tissue. Cancer 1980; 46: 2762-4.
14) Bojar H, Staib W, Beck K, Pilaski J. Investigati-
on on the thermostability of steroid hormone
receptors in lyophilized calf uterine tissue
powder. Cancer 1980; 46: 2770-4.
15) Meyer JS, Rao BR, Stevens SC, White WL. Low
incidence of estrogen receptor in breast carci-
nomas with rapid rates of cellular replication.
Cancer 1977;40:2290-8.
16) Degensheim GA, Bloom N, Tobin E. The value
of progesterone receptor assays in the manage-
ment of advaced breast cancer. Cancer 1980;
46:2789-93.
17) Lippman ME, Allegra JC. Quantitative estrogen
receptor analyses: The response to endocrine
and cytotoxic chemotherapy in human breast
cancer and the disease-free interval. Cancer
1980;46:2829-34.
18) Maass H, Jonat W, Stolzenbach G, Trams G.
The Problem of nonresponding estrogen recep-
tor-positive patients with advanced breast can-
cer. Cancer 1980; 46: 2835-7.
19) Allegra JC, Barlock A, Huff K, Lippmann ME.
Changes in multiple or sequential estrogen
receptor determinations in breast cancer. Can-
cer 1980; 45, 792-4.
20) Fidler IJ, Hardt IR. The origin of metastatic
heterogenity in tumors. Eur J Cancer 1981; 17:
487-94.
21) McCarty KS, Lubahn DB, McCarty KS. Oe-
strogen and progesterone receptors: Physiolo-
gical and pathological considerations. Clin End-
ocrinol Metab 1983; 12 (1); 133-54.
22) Sakai F, Saez S. Existence of receptors bound to
endogenous estradiol in breast cancers of pre-
menopausal and postmenopausal women.
Steroids 1978;27:99-110.